Evidence Hub

Title UNVEILING THE ARTISTRY OF TRITICUM AESTIVUM SPROUTS (TAS): EXPLORING THE POTENTIAL OF TAS EXTRACT IN MIGRAINE PREVENTION AND CONTROL - A PRAGMATIC, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Maaz Ahmad, Mudassar Ali, Hamna Ahmad, Naleem Raheel, F. Anwar, Asma Kanwal, Mussab Ahmad, Daniyal Safdar

Pakistan Postgraduate Medical Journal, 2024

Abstract

Background: Migraine is a relatively common disease that has a significant effect on the daily activities of affected individuals.

Objective:The purpose of this study was to evaluate efficacy of Triticum aestivum sprouts (TAS) extract for prevention and control of migraine.

Methods: A pragmatic,randomized ,doublind ,placebo-controlled clinical trial was conducted in which sixty migrain patients were recruited and randomized to either the TAS extract or placebo group at a 1:1 ratio. The subjects received TAS extract or placebo for four weeks. The major outcome was change in the intensity of headache .

Results: At base line there was no difference between TAS and placebo group regarding pain intensity.All the TAS group patients took the TAS extract for one week.Similarly placebo group was given placebo for the same period.There was a significant difference between these two groups as far as pain intensity was concerned upto the end of 1 week trial

Conclusion: TAS extract had a significant effect on migrain prevention and control.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free